Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| immune cells patterns in VAP | The primary endpoint will be to describe and compare the distribution of immune cells within the lung and the blood before VAP diagnosis (VAP prediction) and at the time of VAP diagnosis. | before and at time of VAP diagnosis |
Not provided
Not provided
Inclusion Criteria:
All the following criteria
Age 18 years or greater
Severe ICU patients hospitalized for one of the above diseases:
NAD > 0.1 µg/kg/min
At least 2 SOFA criteria ≥ 2 points
Exclusion Criteria:
Aspiration pneumonia
Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)
COPD
Smoke inhalation in burn patients
Participation in an intervention study
Pregnant or breastfeeding women
Immunocompromised patients, defined as
Not provided
Not provided
Not provided
ICU Adult patients hospitalized and managed for septic shock or severe trauma (including severe burn) and undergoing mechanical ventilation (within 24h of admission) with an expected length upper than 3 days.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jean-François LLITJOS | Contact | +33761568397 | jeanfrancois.llitjos@biomerieux.com | |
| Marie-Angelique CAZALIS | Contact | +33626807839 | marie-angelique.cazalis@biomerieux.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital Edouard Herriot | Recruiting | Lyon | 69003 | France |
Not provided
| ID | Term |
|---|---|
| D053717 | Pneumonia, Ventilator-Associated |
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D000077299 | Healthcare-Associated Pneumonia |
| D003428 | Cross Infection |
| D007239 | Infections |
| D011014 | Pneumonia |
Not provided
Not provided
Not provided
Not provided
Not provided
Four types of samples are taken for the study per patient at day 4 after ICU admission:
| D012141 |
| Respiratory Tract Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D007049 | Iatrogenic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |